206 related articles for article (PubMed ID: 34119833)
1. Development of photocontrolled BRD4 PROTACs for tongue squamous cell carcinoma (TSCC).
Li Z; Ma S; Yang X; Zhang L; Liang D; Dong G; Du L; Lv Z; Li M
Eur J Med Chem; 2021 Oct; 222():113608. PubMed ID: 34119833
[TBL] [Abstract][Full Text] [Related]
2. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.
Zhang J; Chen P; Zhu P; Zheng P; Wang T; Wang L; Xu C; Zhou J; Zhang H
Bioorg Chem; 2020 Jun; 99():103817. PubMed ID: 32361153
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Zhao L; Li P; Zhao L; Wang M; Tong D; Meng Z; Zhang Q; Li Q; Zhang F
J Cell Biochem; 2020 Feb; 121(2):1855-1869. PubMed ID: 31633227
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
Yang Y; Chen P; Zhao L; Zhang B; Xu C; Zhang H; Zhou J
Bioorg Med Chem; 2021 Jan; 29():115857. PubMed ID: 33191086
[TBL] [Abstract][Full Text] [Related]
7. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
[TBL] [Abstract][Full Text] [Related]
8. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
9. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
10. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
[TBL] [Abstract][Full Text] [Related]
11. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis.
Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
[TBL] [Abstract][Full Text] [Related]
13. BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma.
Wang M; Zhao L; Tong D; Yang L; Zhu H; Li Q; Zhang F
Int Immunopharmacol; 2019 Nov; 76():105921. PubMed ID: 31600692
[TBL] [Abstract][Full Text] [Related]
14. Effects of Curcumin on Squamous Cell Carcinoma of Tongue: An In Vitro Study.
Ardito F; Perrone D; Giuliani M; Testa NF; Muzio LL
Curr Top Med Chem; 2018; 18(3):233-243. PubMed ID: 29651934
[TBL] [Abstract][Full Text] [Related]
15. Light-Induced Protein Degradation with Photocaged PROTACs.
Xue G; Wang K; Zhou D; Zhong H; Pan Z
J Am Chem Soc; 2019 Nov; 141(46):18370-18374. PubMed ID: 31566962
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.
Kong B; Zhu Z; Li H; Hong Q; Wang C; Ma Y; Zheng W; Jiang F; Zhang Z; Ran T; Bian Y; Yang N; Lu T; Zhu J; Tang W; Chen Y
Eur J Med Chem; 2022 Jan; 227():113953. PubMed ID: 34731760
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
Zhao L; Ren Y; Tang H; Wang W; He Q; Sun J; Zhou X; Wang A
Oncotarget; 2015 Dec; 6(42):44538-50. PubMed ID: 26517090
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.
Yoo M; Yoo M; Kim JE; Lee HK; Lee CO; Park CH; Jung KY
Arch Pharm Res; 2018 Jan; 41(1):46-56. PubMed ID: 29103140
[TBL] [Abstract][Full Text] [Related]
19. Obovatol inhibits the growth and aggressiveness of tongue squamous cell carcinoma through regulation of the EGF‑mediated JAK‑STAT signaling pathway.
Duan M; Du X; Ren G; Zhang Y; Zheng Y; Sun S; Zhang J
Mol Med Rep; 2018 Aug; 18(2):1651-1659. PubMed ID: 29845251
[TBL] [Abstract][Full Text] [Related]
20. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma.
Yin C; Jia S; Yang X; Wu L
Eur J Med Chem; 2024 May; 271():116444. PubMed ID: 38691889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]